Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats

Experimental Hematology

Volumn 35, Issue 1, 2007, Pages 164-170

  Jäger, Mark D ^a   Liu, Jian Y ^a,b   Timrott, Kai F ^a   Popp, Felix C ^b   Stoeltzing, Oliver ^b   Lang, Sven A ^b   Piso, Pompiliu ^b   Geissler, Edward K ^b   Schlitt, Hans J ^b   Dahlke, Marc H ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECIPIENT; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; RATS; RATS, INBRED LEW; SIROLIMUS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; WHOLE-BODY IRRADIATION;

ANIMALIA;

EID: 33845725212     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.08.018     Document Type: Article

References (24)

1. Mielcarek M., and Storb R. Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 29 (2003) 283-290
2. Sykes M., and Spitzer T.R. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 110 (2002) 79-99
3. Cosimi A.B., and Sachs D.H. Mixed chimerism and transplantation tolerance. Transplantation 77 (2004) 943-946
4. Maris M., and Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 28 (2003) 13-24
5. Stewart F.M., Zhong S., Wuu J., et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 91 (1998) 3681-3687
6. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
7. Penit C., and Ezine S. Cell proliferation and thymocyte subset reconstitution in sublethally irradiated mice: compared kinetics of endogenous and intrathymically transferred progenitors. Proc Natl Acad Sci U S A 86 (1989) 5547-5551
8. Berzins S.P., Uldrich A.P., Sutherland J.S., et al. Thymic regeneration: teaching an old immune system new tricks. Trends Mol Med 8 (2002) 469-476
9. Mackall C.L., and Gress R.E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 157 (1997) 61-72
10. Beschorner W.E., Tutschka P.J., and Santos G.W. Sequential morphology of graft-versus-host disease in the rat radiation chimera. Clin Immunol Immunopathol 22 (1982) 203-224
11. Stepkowski S.M., Chen H., Daloze P., and Kahan B.D. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 51 (1991) 22-26
12. Ko S., Deiwick A., Jager M.D., et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med 5 (1999) 1292-1297
13. Powell J.D., Fitzhugh C., Kang E.M., et al. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation 80 (2005) 1541-1545
14. Hale D.A., Gottschalk R., Umemura A., Maki T., and Monaco A.P. Immunologic mechanisms in tolerance produced in mice with nonradiation-based lymphoablation and donor-specific bone marrow. Transplantation 74 (2002) 477-484
15. Neipp M., Exner B.G., Maru D., et al. T-cell depletion of allogeneic bone marrow using anti-alphabetaTCR monoclonal antibody: prevention of graft-versus-host disease without affecting engraftment potential in rats. Exp Hematol 27 (1999) 860-867
16. Teshima T., Reddy P., Liu C., et al. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 102 (2003) 429-435
17. Liu J., Farmer Jr. J.D., Lane W.S., et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
18. Hess A.D., Horwitz L., Beschorner W.E., and Santos G.W. Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 161 (1985) 718-730
19. Hess A.D., Bright E.C., Thoburn C., et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 89 (1997) 2203-2209
20. Abraham R.T. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10 (1998) 330-336
21. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998) 335-340
22. Homma M., Damoiseaux J.G., and van Breda Vriesman P.J. Differential effects of cyclosporin-A and rapamycin on in vivo thymocyte maturation. Transplant Proc 29 (1997) 1743-1744
23. Tian L., Lu L., Yuan Z., Lamb J.R., and Tam P.K. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 77 (2004) 183-189
24. Coenen J.J., Koenen H.J., van R.E., Hilbrands L.B., and Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107 (2006) 1018-1023